Three new mixed and mononuclear Ru(II) complexes containing 1,3-thiazolidine-2-thione (tzdtH) were synthesized and characterized by spectroscopic analysis, molar conductivity, cyclic voltammetry, high-resolution electrospray ionization mass spectra and X-ray diffraction. The complexes presented unique stereochemistry and the proposed formulae are: [Ru(tzdt)(bipy)(dppb)]PF6 (1), cis-[Ru(tzdt) 2 (PPh 3 ) 2 ] (2) and trans-[Ru(tzdt)(PPh 3 ) 2 (bipy)]PF 6 (3), where dppb = 1,4-bis(diphenylphosphino)butane and bipy = 2,2′-bipyridine. These complexes demonstrated strong cytotoxicity against cancer cell lines when compared to cisplatin. Specifically, complex 2 was the most potent cytotoxic agent against MCF-7 breast cells, while complexes 1 and 3 were more active in DU-145 prostate cells. Binding of complexes to ctDNA was determined by UV-vis titration and viscosity measurements and revealed binding constant (K b , which are characteristic of compounds possessing weak affinity to ctDNA. In addition, these complexes presented antiparasitic activity against Trypanosoma cruzi. Specifically, complex 3 demonstrated strong potency, moderate selectivity index and acted in synergism with the approved antiparasitic drug, benznidazole. Additionally, complex 3 caused parasite cell death through a necrotic process. In conclusion, we demonstrated that Ru(II) complexes have powerful pharmacological activity, while the metal-free tzdtH does not provoke the same outcome.
Introduction
Cancer is considered a group of complex and multifaceted diseases [1] . Carcinogenesis is thought to be initiated by changes to the DNA within cells and also by inhibition of growth suppressors, which, in turn, gives rise to the uncontrolled cell proliferation, invasion of surrounding and distant tissues, and ultimately leads to a risk of aggressive metastasis [2] . Prostate and breast cancers are of high incidence and mortality around the world and the development of new drugs is of interest [3] . Drugs containing transition metals hold a promising possibility for cancer treatment. Although cisplatin has been largely employed alone or in drug combinations against prostate and breast cancers, limitations regarding resistance has been observed [4, 5] . To overcome cisplatin limitation, Satraplatin, the first orally available Pt drug, is currently undergoing clinical investigation [6] . Ruthenium compounds are promising pharmaceuticals because of many biological features, such as reduced toxicity, suitable biodistribution, and mechanisms of action different than platinum-based compounds [7, 8] [9, 10] . The half-sandwich η cells by inhibiting cathepsin B, a protease related to tumor invasion and metastasis [12, 13] .
Regarding parasitic infections, American trypanosomiasis (Chagas disease) is an important health problem in Latin America, affecting 8-14 million people (14,000 deaths per year) with different forms of the pathology [14, 15] . It is of great concern due to the development of chronic cardiomyopathy and other related health problems [16] . Chemotherapy is only based on nifurtimox and benznidazole (Bdz), drugs that are more than 50 years old and suffer from low efficacy and high levels of toxicity [17] . Since the discovery of an efficient Ru(II) complex containing clotrimazole against Trypanosoma cruzi, a large number of metal complexes have been evaluated for this purpose [18] . Strategies for the development of new anti-trypanosomal metallodrugs generally involve: coordination of antiparasitic ligands to the metal, and coordination of DNA intercalators to the metal and metal compounds as direct inhibitors of parasite enzymes [19, 20] .
In view of this, our research group has been studying a number of pharmacological properties for Ru(II) complexes containing phosphines and diimines ligands as anticancer and anti-infectious agents [21] [22] [23] [24] [25] [26] [27] . Remarkable activities were observed for complexes with general formulae [Ru(pic)(dppb)(N-N)]PF 6 , where pic = 2-pyridinecarboxylate; N-N = 2,2-bipyridine or 1,10′-phenanthroline. These complexes displayed strong in vitro activity against Mycobacterium tuberculosis and more importantly, presented activity against multi-resistant strains. In view of these results with bidentate N,O-ligand (pic), we sought to investigate Ru complexes containing bidentate N,S-ligands. In fact, heterocyclic N,S-ligands have been extensively used in the preparation of metal complexes for therapeutic application [27] [28] [29] . Among them, an interesting ligand is 1,3-thiazolidine-2-thiol (tzdtH), which has a classical thiol/thione tautomerism as shown in Fig. 1 . Crystallographic studies for tzdtH structure indicate that the thione tautomer (form II; Fig. 1 ) is present in the solid state [30] . However, two tautomeric forms can be found in aqueous and in organic solutions (i.e., 1,4-dioxane, CCl 4 , benzene, CHCl 3 , CH 2 Cl 2 , C 2 H 4 Cl 2s , EtOH, MeOH, CH 3 CN, DMF and DMSO) [31, 32] . Given this promising outlook and considering the different coordination sites of the tzdtH [33] [34] [35] , this work aimed to study the reactivity of this ligand with Ru(II) phosphine precursors. To the best of our knowledge, only three ruthenium organometallic compounds with anionic tzdt − are described in the literature, however no detailed structural as well as pharmacological evaluation were carried out [36, 37] 
X-ray diffraction
Single crystals of the complexes were grown from diethyl ether diffusion into a dichloromethane solution of complex at room temperature (293 K). X-ray diffraction experiments were carried out at room temperature using a suitable crystal mounted on glass fiber, and positioned on the goniometer head. Intensity data were measured on an EnrafNonius Kappa-CCD diffractometer with graphite monochromated MoKα radiation (λ = 0.71073 Å). The cell refinements were performed using the software Collect [41] and Scalepack [42] , and the final cell parameters were obtained on all reflections. The structures were solved by direct method using SHELXS-97 and refined using the software SHELXL-97. In all complexes' structures, the Gaussian method was used for the absorption corrections [43] . Non-hydrogen atoms of the complexes were unambiguously located, and a full-matrix, leastsquares refinement of these atoms with anisotropic thermal parameters was carried out. In all ligands of the complexes, aromatic C-H hydrogen atoms were positioned stereochemically and were refined with fixed individual displacement parameters [U iso (H) = 1.2 U eq (Csp 2 )] using a riding model with aromatic, C-H bond lengths which were fixed at 0.93 Å. Methylene groups of tzdt ligand were also set as isotropic with a thermal parameter 20% greater than the equivalent isotropic displacement parameter of the atom to which each one was bonded and C-H bond lengths were fixed at 0.97 Å. Tables were generated by WinGX and the structure representations by MERCURY. The CrystalExplorer 2.1 program was used to generate the Hirshfeld surfaces and the fingerprint plot. The Hirshfeld surfaces were employed to define the intermolecular environment of molecules within the crystal of each complex [44] [45] [46] . The fingerprint plot or 2D-fingerprint graphics is constructed by the plot of de versus di (de = external distance is defined as the distance between the calculated Hirshfeld surface and the nearest atom of an adjacent molecule; di = internal distance is distance between the nearest nucleus internal and the calculated Hirshfeld surface). Relationships between crystal packing pattern and molecular geometry were determined by analyzing parameters present in Hirshfeld fingerprint plots. The 2D-fingerprint also provides the percentage of each intermolecular contact occurring in the complex structure. Crystallography data were registered in the Cambridge Crystallographic Data Centre (CCDC), with the respective deposit numbers: 1037025 (1), 1037026 (2) and 1037027 (3).
DNA binding 2.4.1. Spectroscopic titration
A solution of calf thymus DNA (ctDNA, Sigma-Aldrich) was prepared in Tris-HCl buffer (5 mM Tris-HCl, pH 7.2). A solution of ctDNA in the buffer gave a ratio of UV absorbance at 260 and 280 nm of about 1.8:1, indicating that the solution is protein-free. The concentration of ctDNA was measured from its absorption intensity at 260 nm using the molar absorption coefficient value of 6600 M − 1 cm − 1 [47] . Solutions of Ru(II) complexes used in the experiments were prepared in Tris-HCl buffer containing 5% DMSO. To the ctDNA titration experiments, different concentrations of the ctDNA were used (ranging 3.8 × 10 and 3, respectively. Sample correction was done for the absorbance of DNA and the spectra were recorded after solution equilibration for 2 min. It is worth mentioning that complex 2 and 3 structures change after incubating in the buffered medium, such as observed in the 31 P NMR spectrum of complexes 2 and 3 (see the Supplementary material). These chances can be attributed to exchange of the monodentate PPh 3 ligand. As a result, the signal of PPh 3 free is observed at around −6.3 ppm. The intrinsic equilibrium binding constant (K b ) of the complexes to ctDNA was obtained using the McGhee-von Hippel (MvH) method [48] by using the expression of Wolfe and co-workers [49] :
is the concentration of ctDNA in base pairs, ε a is the ratio of the absorbance/[Ru(II) complex], ε f is the extinction coefficient of the free Ru(II) complex, and ε b is the extinction coefficient of the complex in the fully bound form. The ratio of the slope to the intercept in the plot of [ctDNA]/(εa-εf) vs.
[ctDNA] gives the value of K b , which was calculated from the metal to ligand charge transfer (MLCT) absorption band (λ max ). Changes in the absorption intensity increasing concentration of ctDNA was monitored and analyzed by regression analysis. The nonlinear least-squares analysis was calculated by using OriginLab.
Viscosity measurements
Viscometric titrations of 1-3 were performed using an Ostwald viscometer in a constant temperature (37°C). ) obtained from BALB/c mice were seeded in a 24 well-plate with rounded coverslips on the bottom in RPMI supplemented with 10% FBS and incubated for 24 h. Cells were then infected with trypomastigotes (10:1) for 2 h. Free trypomastigotes were removed by successive washes using saline solution and the cells were incubated for 24 h for internalization and differentiation of trypomastigotes into amastigotes. Following this, cultures were incubated in complete medium alone or with compounds for 72 h. Cells were fixed in absolute alcohol and the percentage of infected macrophages and the number of amastigotes/100 macrophages was determined by manual counting after hematoxylin and eosin staining using an optical microscope (Olympus, Tokyo, Japan). The percentage of infected macrophages and the number of amastigotes per 100 macrophages was determined by counting 100 cells per slide.
The one-way ANOVA and Bonferroni for multiple comparisons were used to determine the statistical significance of the group comparisons. Benznidazole was used as the positive control.
Propidium iodide and annexin V staining
Trypomastigotes (1 × 10 7 ) were incubated for 24 h at 37°C in the absence or presence of Ru(II) complex 3 (0.01, 0.015 or 0.02 μM). After incubation, the parasites were labeled for propidium iodide (PI) and annexin V using the annexin V-FITC apoptosis detection kit (Sigma-Aldrich), according to the manufacturer's instructions. Acquisition and analyses was performed using a FACS Calibur flow cytometer (Becton Dickinson, CA, USA), with FlowJo software (Tree Star, CA, USA). A total of 30,000 events were acquired in the region previously established as trypomastigote forms of T. cruzi. Two independent experiments were performed.
Results

Synthesis, infrared spectroscopy and mass spectrometry
The chemical reactivity of tzdtH in triethylamine was studied under the presence of metal complexes cis-[RuCl 2 (dppb) ( 
Electrochemical study
The redox behavior of metal complexes was investigated by cyclic voltammetry (Fig. 2) . Complexes 1-3 revealed one-electron waves for Ru(II)/Ru(III) redox process with quasi-reversible behavior at +1150, +690 and +926 mV. These values highlight the different stereochemistry around the Ru(II) center. Complex 2 exhibited redox process in lower potential than complexes 1 and 3. This can be explained because of two molecules of tzdt − and the absence of bipy, which is a wellknown π-electron acceptor ligand. In fact, the bipy-containing complexes 1 and 3 presented Ru(II)/Ru(III) oxidation peaks around 1000 mV, which are similar values to Ru(II) complexes described in the literature [25, 26] . Despite complexes 1 and 3 presenting the same ligands, 3 has a redox potential much lower than 1. This may be explained by the competition for electron density around the metal between the phosphorus atoms in trans position observed in complex 3 [27] . The half-wave potential (E½) values for these complexes were more anodic than the starting reactants by approximately 0.60 V (Table 1) .
This indicates that ruthenium is more easily oxidized in metal precursors than complexes (1-3), therefore complexes (1-3) are more stable than their starting reactants. This stabilization is possible due to the replacement of two σ and π donor chlorides by a negative and monocharged chelating tzdt − , which contains an acceptor group.
NMR spectroscopy
Resonance for complexes 1 and 2 was carried out in CDCl 3 , while acetone-d 6 with the high field signal corresponding to the P trans N, as previously described [40] . These assignments are based on an empirical linear correlation established between crystallographic determined Ru-P distances in a series of Ru-dppb complexes and the corresponding 31 P chemical shift observed in solution, in which the chemical shift become more high-field with increasing Ru-P bond length [50] . In view of this information, we suggest that in complex 1 the high-field doublet belongs to the P trans to nitrogen from bipy, because the Ru-P2 distance of 2.3299(9) Å (trans bipy) is longer than that observed for the Ru-P1 trans of nitrogen of the 2-MT ligand [2.3069 (9) [52] . These values are typical of PPh 3 trans to PPh 3 as observed for a series of ruthenium compounds [53, 54] . The 1 H NMR spectrum of metal-free tzdtH in CDCl 3 displayed a broad singlet corresponding to the proton of the N-H group around 7.30 ppm and a pair of triplets in the range 3.50-4.00 ppm corresponding to the methylenic protons. displayed signals around 183-181 ppm, depending on the complex, typical of the CS coordinated group. This signal is shielded compared with that observed for the free ligand which occurs at 201.7 ppm, indicating that sulfur is coordinated to the metal. In addition, complexes displayed signals in the range 57.4-55.3 and 32.0-31.7 ppm, typically assigned to carbon atoms of the N-CH 2 and S-CH 2 groups of the thiazolidine ring, respectively.
X-ray crystal structures
Suitable crystals for a single crystal X-ray structure determination were obtained by slow evaporation of a chloroform solution. The MERCURY plots in Fig. 3 show that these complexes possess a distorted octahedral geometry. Crystal data collections and structure refinement parameters are summarized in Table 1S . The crystallographic analysis of metal-free tzdtH described in the literature shows that C1-S1 is a double bond, while C1-N1 single-bond [54] . When tzdtH is coordinated to Ru, the length of these bonds significantly changes in which the C1-S1 is longer whereas C1-N1 is shorter in all the complexes. This suggests that the ligand adopts the canonical form (III) depicted in Fig. 1 . In the crystal structure of complex 3, the Ru-P bond lengths are longer than the other two complexes, possible due to the P to P trans influence. In contrast, the Ru-N1 length in 3 is shorter than that the observed for complexes 1 and 2, because of the P to N trans influence which slightly affects the Ru-N bond length.
When we analyze the tzdt − conformation, a planar conformation in complexes 1 and 3 is observed, while in complex 2 a twisted ring is observed in the ligand structure. Due to the intermolecular interaction and crystal packing, the free tzdtH in solid state adopts either a distorted or a planar conformation. In the crystal structure of the neutral complex 2, a sulfur⋯sulfur contact is observed, which explains the tzdtH distorted conformation. The distance of S⋯S atoms in the structure of complex 2 is at 3.543 Å as shown in Fig. 4 , being shorter than the sum of the van der Waals radius (3.60 Å).
To examine the spatial arrangement of Ru complexes, the intermolecular contacts of each crystal structure were determined by using the Hirshfeld surfaces and their corresponding 2D-fingerprint plots (Supplementary material). The relative contribution of the intermolecular contacts present in these complexes shares interesting structural features. In complex (1), the contribution is: H⋯H (55.1%), C⋯H (17.2%), F⋯H (15.9%), S⋯H (7.9%), C⋯C (1.4%), C⋯F (0.5%), S⋯F (0.4%), and N⋯H (0.4%). In comparison to complex 1, the intermolecular contribution found in 2 is slightly different [H⋯H (63.6%), C⋯H (17.5%), Fig. 3 . Crystal structures of complexes 1, 2 and 3 with selected atoms labeled. Ellipsoids are represented at 30% of probability. S⋯H (17.5%), C⋯C (0.8%), S⋯C (0.2%)]. For complex 2, the Hirshfeld surface analysis highlights the intermolecular contacts between S⋯S with contribution of 0.3%, which is absent in other complexes, this kind of contact can be seen in Fig. 4 . The contribution to Hirshfeld surface in complex 3 [H⋯H (48.7%), C⋯H (19.0%), F⋯H (13.7%), S⋯H (6.3%), C⋯C (0.6%)] is similar to that observed in complex 1. In all of them, the H⋯H contacts compose about 50% of the Hirshfeld surface, evidencing the importance of van der Waals forces to crystal packing stabilization. In vitro cytotoxicity against DU-145 prostate and MCF-7 breast cancer cells was examined 48 h after incubation with drugs and the results were expressed by determining the IC 50 values. Cisplatin was the reference cytotoxic drug. For comparison reason only, metal-free ligands tzdtH, dppb, bipy and PPh 3 were tested as well. The results are summarized in Table 2 .
All the complexes displayed cytotoxicity against cancer cells, while none metal-free ligands were cytotoxic in concentrations up to 200 μM. These observations strongly suggests that Ru(II) associated with the ligands are responsible for the cytotoxicity in cancer cells. Importantly, the Ru(II) complexes were more active than cisplatin. A comparison between the complexes revealed that compound 1 is potent against the two cancer cell lines, while 2 is more cytotoxic against breast than prostate cells. Complex 1 was particularly more potent against prostate cells, while compound 3 was against breast cells. Complex 2 was less active among the complexes.
Based on the cytotoxicity of these Ru(II) complexes against cancer cells, it was hypothesized that these complexes may interact with ctDNA. To verify this, the interaction with ctDNA was studied via spectroscopic titration (Fig. 5a ). Under the presence of the Ru(II) complexes, a ctDNA hypochromism in the range of 29-35% was observed, which indicates that metal complexes form a ternary complex with ctDNA. In addition, the binding constant (K b ) were determined and the respective values found were: 1.0, 1.7 and 4.9 × 10 3 M − 1 for complexes 1, 2 and 3. These values indicate a weak interaction with ctDNA when compared to a classical ctDNA intercalator ethidium bromide (K b 10 6 M − 1 ) [55] . Interestingly, complex 1 was the most active anticancer drug, but it presented lower ctDNA than complex 3, which was less cytotoxic. Moreover, viscosity analysis of ctDNA-binding revealed that viscosity is not modified when the concentration of a Ru(II) complex increases. This supports the idea that ruthenium complexes have a weak interaction, possibly by an electrostatic mode [56] . A plausible interpretation for this observation is that the binding of Ru(II) complexes to ctDNA is not via intercalation, due to the absence of planar ligands.
Antiparasitic activity
The antiparasitic evaluation against bloodstream trypomastigotes of T. cruzi parasite revealed that metal-free tzdtH and complex 2 have no activity in a concentration up to 10 μM. In contrast, complexes 1 and 3 exhibited strong activity (Table 2) . Complex 3 displayed the highest antiparasitic activity, being more potent than benznidazole, the reference antiparasitic drug. Additionally, complex 3 had little effect on J774 macrophage viability, therefore showing that the antiparasitic activity for this complex was achieved with great selectivity index. Regarding the structure-activity relationships, active antiparasitic complexes containing a bipy ligand were observed, while complex 2 lacking bipy was inactive. Therefore, these observations suggest that the presence of bipy as well as a positive charge present in the structures of complexes 1 and 3 contribute to antiparasitic activity.
Evaluation in T. cruzi-infected macrophages
After observing that complex 3 has potent and selective activity against the extracellular parasite, its antiparasitic activity against the intracellular form of T. cruzi was investigated (Fig. 6) . In comparison to untreated infected macrophages, complex 3 treatment reduced the percentage of infected macrophages. Moreover, this treatment reduced the mean number of amastigotes per 100 macrophages. Importantly, complex 3 at 0.1 μM has comparable antiparasitic activity to benznidazole, the positive control. Therefore, these results show that this complex has antiparasitic activity against the intracellular and proliferative amastigote form. Since amastigote proliferation is pivotal within parasite cell cycle, it is plausible that these compounds impair the parasite cell cycle development inside host cells.
Given this strong antiparasitic activity, it was investigated whether the Ru(II) complexes have enhanced activity in drug combination with benznidazole. As shown in Fig. 7 , drug combination of benznidazole at 5 μM plus complex 3 at 0.05 μM reduced the percentage of infected macrophages as well as the number of amastigotes more than each drug alone (Fig. 7, panels A, B) . Importantly, the drug combination displayed stronger activity than benznidazole alone at a high concentration (10 μM). When the concentration of complex 3 was increased at 0.1 μM and added in combination to benznidazole at 5 μM, in practice no intracellular parasites were observed (Fig. 7, panels  C, D) . These results indicate that drug combination of benznidazole and complex 3 has enhanced antiparasitic activity.
Parasite cell death
After ascertaining the antiparasitic activity of complex 3, it was investigated how this complex causes parasite cell death. In comparison to untreated trypomastigotes (Fig. 8, panel A) , complex 3 treatment lead to single PI staining and double PI + annexin V staining, which are characteristics of necrosis and late apoptosis, respectively. As observed by comparing panels B-D, complex 3 causes cell death in a concentration-dependent manner. Therefore, the Ru complex causes parasite cell death mainly by inducing necrosis.
Conclusions
Here we demonstrated the great chemical versatility of tzdtH, which is able to react with phosphine-, diamine-and phosphine/diamine-Ru precursors. The X-ray crystallography analyses revealed the exact structures of the complexes [Ru(tzdt)(bipy)(dppb)]PF 6 (1), cis-[Ru(tzdt) 2 (PPh 3 ) 2 ] (2) and trans-[Ru(tzdt)(PPh 3 ) 2 (bipy)]PF 6 (3) and highlighted that the tzdt heterocyclic ring can assume a planar or twisted conformation under metal coordination. The electrochemical profile of these Ru complexes pointed out that tzdt provided resistance toward oxidation than the precursor complexes. These complexes exhibited strong anticancer and antiparasitic activity, while the metal-free tzdtH do not provoke the same outcome. Regarding the anticancer activity, the new complexes exhibited cytotoxicity against prostate and breast cancer cells. They were more potent than cisplatin and more cytotoxic for cancer than normal cells (macrophages), indicating a degree of selectivity. Regarding the antiparasitic activity against T. cruzi, these complexes exhibited a broad spectrum of action (extracellular, intracellular forms). Flow cytometry analysis revealed that complex 3 destroys parasite cells, indicating this is more likely a parasiticidal than a cytostatic drug. These complexes arrested the parasite cell cycle and strongly affected the intracellular development and ultimately caused irreversible parasite death through a necrotic process. An important aspect in the anticancer and antiparasitic therapy is the drug combination. Here it was observed that Ru(II) complexes exhibit enhanced antiparasitic activity when given in combination with the antiparasitic drug benznidazole. This points out that these complexes are suitable molecules for drug combination compositions.
